Abstract 340P
Background
The optimal follow-up strategy for the detection of relapse in patients with diffuse large B-cell lymphoma (DLBCL) has not been clarified. In this report, we assess the role of laboratory tests and CT for surveillance and investigate the risk factors for recurrence.
Methods
We reviewed the clinical records of patients who achieved CR by PET-CT after received R-CHOP like regimen in our hospital for DLBCL between February 2008 and February 2022. Clinical evaluation post treatment was done every 3-6 months in the first 2 years, and every 6–12 years in the 3 coming years.
Results
A total of 324 patients were eligible for inclusion in this study. The median duration of follow-up for surviving patients was 4.3 years. The cumulative incidence of relapse without death at 2 and 5 years was 13.3% and 21.6%. Overall, 1453 CT scans were carried out through surveillance. The total of 64 patients relapsed within the observation period. Of these, 19 patients were detected to have recurrence on surveillance CT scans. On univariate analysis, ABC-type, extranodal (EN) stites > 1 at diagnosi, and relative dose intensity (RDI) < 90% were risk factors for recurrence. On Fine-Gray regression analysis, ABC-type (HR 2.1, 95% confidence interval [95% CI] 1.1-3.7. p=0.018) and EN sites > 1 at diagnosis (HR 1.8, 95% CI 1.1-3.6. p=0.031) were independent risk factors for recurrence. The area under the curve (AUC) of the receiver operating characteristic (ROC) curve of the surveillance value of soluble interleukin-2 (sIL-2R) (HR 0.81, 95% CI 0.72–0.90) was significantly larger than lactate dehydrogenase (LDH) (0.65, 95% CI 0.55–0.75. p=0.024). While in the normal pretreatment sIL-2R group, the AUC of the ROC curve of sIL2R was small (0.57), however, in the high pretreatment sIL-2R group, the AUC of the ROC curve of sIL2-R (0.83, 95% CI 0.74-0.91) was high. We defined the best cutoff value of the sIL2-R as 607.5 using a ROC curve in the high pretreatment sIL-2R group (Sensitivity 0.63. Specificity 0.88).
Conclusions
Routine surveillance CT scans were of limited value in detecting asymptomatic relapse. ABC-type and EN sites were independent risk factors for recurrence. The measurement of sIL-2R might be useful for surveillance.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract